Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

pharma

  • Home
  •  
  • pharma



  • Most Read
  • Latest Comments
  • Vita Life Sciences reports sales growth of $4m as it launches in Vietnam
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Vita Life Sciences reports sales growth of $4m as it launches in Vietnam
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Vita Life Sciences reports sales growth of $4m as it launches in Vietnam
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Vita Life Sciences reports sales growth of $4m as it launches in Vietnam
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Vita Life Sciences reports sales growth of $4m as it launches in Vietnam
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • BTC Health secures $5m ECMO contract with Royal Children’s Hospital for life-saving medtech
    BTC Health secures $5m ECMO contract with Royal Children’s Hospital for life-saving medtech
    • News

  • BTC Health drives earnings with product diversification to all major hospital operators
    BTC Health drives earnings with product diversification to all major hospital operators
    • News

  • Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    • News

  • SDI reports profit upgrade with cost cutting measure proving effective
    SDI reports profit upgrade with cost cutting measure proving effective
    • News

  • Mayne Pharma settles shareholder class action for $38M with no admission of guilt
    Mayne Pharma settles shareholder class action for $38M with no admission of guilt
    • News

  • Vita Life Sciences reports sales growth of $4m as it launches in Vietnam
    • News

    Vita Life Sciences reports sales growth of $4m as it launches in Vietnam

    Pharmaceutical and healthcare company Vita Life Sciences (ASX: VLS) has forecasted a positive growth trajectory for the first half of CY24. Besides expecting sales growth, it is also expecting returns from its recent product launch in Vietnam.  The Company expects sales to rise to between $39 million and $40 million, up from $34.7 million in

    Read More
    Public
  • Firebrick’s nasal hygiene spray launched in the US without FDA approvals
    • News

    Firebrick’s nasal hygiene spray launched in the US without FDA approvals

    Pharmaceutical company Firebrick Pharma (ASX: FRE)’s Nasodine Nasal Spray has been launched in the United States and can now be purchased from the Company’s US website with online promotions will commencing this week across the US.  In the US, Nasodine will be promoted for ‘nasal hygiene’ without any therapeutic claims. Based on legal advice obtained

    Read More
    Public
  • Garvan Institute preclinical study identifies potential of Pharmaxis drug to boost pancreatic cancer survival rate by 35%
    • News

    Garvan Institute preclinical study identifies potential of Pharmaxis drug to boost pancreatic cancer survival rate by 35%

    Each year, more than 4,000 Australians are diagnosed with pancreatic cancer, a form of cancer which is difficult to diagnose and with limited treatment options. Thanks to a new study conducted by the Garvan Institute of Medical Research, however, a drug developed by biotech company Pharmaxis (ASX: PXS) could increase patient survival rates by 35%. 

    Read More
    Public
  • Neurotech reports clinical trial results for world first Autism Spectrum Disorder drug
    • News

    Neurotech reports clinical trial results for world first Autism Spectrum Disorder drug

    Autism Spectrum Disorder (ASD) affects 1 in 150 Australians. Boys are 4 times more likely to have it than girls, and symptoms are noticeable at around 2-3 years of age. According to the Australian Institute of Health and Welfare, the number of people with ASD in Australia is increasing, providing an impetus for biopharmaceutical company

    Read More
    Public
  • Why reinvent the wheel? Starpharma is using their tech to improve existing drugs
    • News

    Why reinvent the wheel? Starpharma is using their tech to improve existing drugs

    We live in the age of optimisation. Constantly asking questions like how can we be more efficient? How can we streamline processes? How can we enhance ourselves with the resources available?  The pharmaceutical scene is no different, seeking to optimise drugs in any way possible to produce better patient outcomes.  Biopharmaceutical company Starpharma (ASX: SPL)

    Read More
    Public
  • Will this drug be the solution to social anxiety issues of upcoming generations?
    • News

    Will this drug be the solution to social anxiety issues of upcoming generations?

    Where kids of yesteryear might have been labelled shy due to hesitations in social situations, coming generations of children will be classified as having Social Anxiety Disorder as a result of hypervigilant parenting in the digital age. While some will be self-treated via social experimentation, others will struggle without medical intervention which is just one

    Read More
    Public
  • 1
  • 2
  • 3

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.